Targeting Amyloid and Tau: Current and Emerging Therapies

The pathological accumulation of amyloid-beta plaques and tau tangles remains a hallmark of Alzheimer’s disease. This session will explore current therapies targeting amyloid and tau, as well as novel strategies in development. The discussion will cover FDA-approved drugs, such as anti-amyloid monoclonal antibodies, and new clinical trial results from drugs aiming to halt or reverse tau pathology. By addressing these core pathologies, this track will focus on how therapeutic interventions may modify disease progression.
 

    Related Conference of Targeting Amyloid and Tau: Current and Emerging Therapies

    October 24-25, 2024

    13th World congress on Addictive Disorders & Addiction Therapy

    Zurich, Switzerland
    February 17-18, 2025

    42nd Global Psychiatry and Mental Health Conference

    Paris, France
    February 20-21, 2025

    5th World Conference on Addiction Psychiatry

    Amsterdam, Netherlands
    February 24-25, 2025

    6th Annual Congress on Psychiatry

    London, UK
    March 10-11, 2025

    5th Annual Congress on Mental Health

    Paris, France
    March 10-11, 2025

    7th International Congress on Mental Health

    Paris, France
    April 07-08, 2025

    39th International Conference on Psychiatry and Mental Health

    Amsterdam, Netherlands
    April 14-15, 2025

    3rd World Congress on Psychiatry

    Budapest, Hungary
    May 21-22, 2025

    7th European Autism Congress

    Paris, France
    June 16-17, 2025

    3rd International Conference onPsychiatry and Psychology

    Zurich, Switzerland
    June 16-17, 2025

    10th International Conference on Addiction Therapy

    Zurich, Switzerland
    June 16-17, 2025

    35th Euro Congress on Psychiatrists and Psychologists

    Frankfurt, Germany

    Targeting Amyloid and Tau: Current and Emerging Therapies Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in